- Home
- QNCX vs ASRT Comparison
QNCX vs ASRT Comparison
Compare QNCX & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QNCX | ASRT |
|---|---|---|
| Founded | 2012 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.0M | 76.0M |
| IPO Year | 2019 | 2004 |
Fundamental Metrics
Financial Performance| Metric | QNCX | ASRT |
|---|---|---|
| Price | $0.10 | $11.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $10.00 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 33.4M | 24.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 95.07 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $124,961,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.09 | $0.51 |
| 52 Week High | $4.55 | $12.95 |
Technical Indicators
Market Signals| Indicator | QNCX | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 27.86 | 50.67 |
| Support Level | $0.09 | $11.05 |
| Resistance Level | $0.98 | $12.45 |
| Average True Range (ATR) | 0.01 | 0.46 |
| MACD | 0.09 | -0.15 |
| Stochastic Oscillator | 18.57 | 38.46 |
Price Performance
Historical ComparisonAbout QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.